11-Ketotestosterone and 11-Ketodihydrotestosterone in Castration Resistant Prostate Cancer: Potent Androgens Which Can No Longer Be Ignored
Open accessThe DOI matches its Crossref record; 55 of the 55 references it cites were found in a registry or an index.
Abstract
Dihydrotestosterone (DHT) is regarded as the most potent natural androgen and is implicated in the development and progression of castration resistant prostate cancer (CRPC). Under castrate conditions, DHT is produced from the metabolism of the adrenal androgen precursors, DHEA and androstenedione. Recent studies have shown that the adrenal steroid 11β-hydroxyandrostenedione (11OHA4) serves as the precursor to the androgens 11-ketotestosterone (11KT) and 11-ketodihydrotestosterone (11KDHT). In this study we comprehensively assess the androgenic activity of 11KT and 11KDHT. This is the first study, to our knowledge, to show that 11KT and 11KDHT, like T and DHT, are potent and efficacious agonists of the human androgen receptor (AR) and induced both the expression of representative AR-regulated genes as well as cellular proliferation in the androgen dependent prostate cancer cell lines, LNCaP and VCaP. Proteomic analysis revealed that 11KDHT regulated the expression of more AR-regulated proteins than DHT in VCaP cells, while in vitro conversion assays showed that 11KT and 11KDHT are metabolized at a significantly lower rate in both LNCaP and VCaP cells when compared to T and DHT, respectively. Our findings show that 11KT and 11KDHT are bona fide androgens capable of inducing androgen-dependant gene expression and cell growth, and that these steroids have the potential to remain active longer than T and DHT due to the decreased rate at which they are metabolised. Collectively, our data demonstrates that 11KT and 11KDHT likely play a vital, but overlooked, role in the development and progression of CRPC.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures

![Fig 2 Binding of DHT, T, 11KDHT and 11KT to the human AR (A) and transactivation via an ARE (B and C). Binding affinities, agonist potencies and efficacies of DHT, 11KDHT, T and 11KT relative to the synthetic AR agonist mibolerone are summarised in (D). Whole cell binding assays (A) were conducted in COS-1 cells transiently transfected with pSVARo. Cells were incubated with 0.2 nM [3H]-Mib in the absence and presence of increasing concentrations of either unlabelled Mib, DHT, 11KDHT, T and 11KT for 16 hours. Results are plotted as % specific binding where the total specific binding of [3H]-Mib only is set to 100% and binding of unlabelled steroid is set as a % binding relative to that. Whole cell binding results are shown as means ± SEM of three independent experiments performed in triplicate. Transactivation assays (B and C) where performed in COS-1 cells transiently transfected with the pSVARo expression vector and the 4xSC ARE1.2-luc reporter. Agonist activity was measured by incubating cells in the presence of increasing concentrations of either Mib, DHT, T, 11KDHT or 11KT for 24 h. Induction is shown as % luciferase activity expressed in relative light units (rlu’s), with the maximal response of Mib (10−5 M) set to 100%. Luciferase assays are shown as means ± SEM of six independent experiments performed in quadruplicate.](https://figures.cochat.ai/paper-figures/99618cf761a440d99d5228b87dbb6f76/11-ketotestosterone-and-11-ketodihydrotestosterone-in-castration-resistant-figure-2.jpg)
![Fig 3 Induction of AR-regulated gene expression in LNCaP cells by DHT, 11KDHT and 11KT. Cells were incubated with CS-FCS-supplemented media for 24 hours prior to treatment with 1 or 10 nM steroid for an additional 24 hours prior to analysis by qPCR. Gene expression was calculated relative to the geometric mean of the reference genes ALAS and PBGD. Fold change over vehicle was calculated using the method described by Pfaffl et al [48]. Results are shown as means ± SEM of three independent experiments performed in triplicate. Data from individual experiments was all normalized using log transformation and mean-centering prior to analysis [49].](https://figures.cochat.ai/paper-figures/041a5f66ce2c452490998750f1db4851/11-ketotestosterone-and-11-ketodihydrotestosterone-in-castration-resistant-figure-3.jpg)
![Fig 4 Induction of AR-regulated gene expression in VCaP cells by DHT, 11KDHT, T and 11KT. Cells were incubated with CS-FCS supplemented media for 24 hours prior to treatment with 1 or 10 nM steroid for an additional 24 hours prior to analysis by qPCR. Gene expression was calculated relative to the geometric mean of the reference genes ALAS and PBGD and are expressed as the fold change over the vehicle control. Results are shown as means ± SEM of three independent experiments performed in triplicate. Data from individual experiments was all normalized using log transformation and mean-centering prior to analysis [49].](https://figures.cochat.ai/paper-figures/10542b2cdd9f4e1fbc1285f06a05c43b/11-ketotestosterone-and-11-ketodihydrotestosterone-in-castration-resistant-figure-4.jpg)


Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“11KA4 in turn serves as a substrate for AKR1C3 expressed in peripheral tissues such as adipose tissue, yielding 11KT, which binds and activates the human androgen receptor with an affinity and potency similar to that of testosterone [45,[70], [71], [72]].”
From Human steroid biosynthesis, metabolism and excretion are differentially reflected by serum and urine steroid metabolomes: a comprehensive review (2019) · cites this paper as [71]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“11KT is a potent androgen, with bioactivity similar to that of T (25–27).”
From 24-Hour Profiles of 11-Oxygenated C19 Steroids and Δ5-Steroid Sulfates during Oral and Continuous Subcutaneous Glucocorticoids in 21-Hydroxylase Deficiency (2021) · cites this paper as [27]
The cited source says what the claim attributes to it.
In the citing paper
“11KT can activate androgen-dependent processes with a similar potency to T12”
From Steroid hormone profiling reveals altered adrenal androgen production in endometriosis (2026) · cites this paper as [12]
In the citing paper
“including, 11ketotestosterone and 11-keto-DHT, androgens that bind and activate the androgen receptor.128,129”
From Congenital adrenal hyperplasia (2017) · cites this paper as [128]
In the citing paper
“While 11OHT and 11OHDHT represent partial AR agonists, 11KT and 11KDHT are full agonists with the same AR activating potential as T and DHT, respectively (Pretorius et al., 2016, Storbeck et al., 2013).”
From Intracrine androgen biosynthesis, metabolism and action revisited (2018) · cites this paper as Pretorius et al., 2016
4 more claims about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
A new mathematical model for relative quantification in real-time RT-PCR
Pfaffl, M. W. (2001) · Nucleic Acids Research · doi:10.1093/nar/29.9.e45 · Cited by 34,610
Primer-BLAST: A tool to design target-specific primers for polymerase chain reaction
Ye, J., Coulouris, G., Zaretskaya, I., Cutcutache, I., Rozen, S., & Madden, T. L. (2012) · BMC Bioinformatics · doi:10.1186/1471-2105-13-134 · Cited by 6,111 · cited 1×
“Reference genes: PBGD [28]: 5’-CATGTCTGGTAACGGCAATG-3’ (forward) and 5’GTACG AGGCTTTCAATGTTG-3’ (reverse), ALAS [29]: 5’-TTCCACAGGAGCCAGCATAC-3’ (forward) and 5’-GGACCTTGGCCTTAGCAGTT-3’ (reverse).”
Increased Survival with Enzalutamide in Prostate Cancer after Chemotherapy
Scher, H. I., Fizazi, K., Saad, F., Taplin, M.-E., Sternberg, C. N., Miller, K., de Wit, R., Mulders, P., Chi, K. N., Shore, N. D., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1207506 · Cited by 4,586 · cited 1×
“Recent clinical trials demonstrating beneficial clinical outcomes after treatment with the AR antagonist enzalutamide [7] and the CYP17A1 inhibitor abiraterone [8–10] have highlighted the continued androgen dependency of CRPC.”
BackgroundAbiraterone and Increased Survival in Metastatic Prostate Cancer
de Bono, J. S., Logothetis, C. J., Molina, A., Fizazi, K., North, S., Chu, L., Chi, K. N., Jones, R. J., Goodman, O. B., Saad, F., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1014618 · Cited by 4,407
LNCaP model of human prostatic carcinoma.
Horoszewicz, J. S., Leong, S. S., Kawinski, E., Karr, J. P., Rosenthal, H. E., Chu, T. M., MIRAND, E. A., & Murphy, G. P. (1983) · PubMed · Cited by 1,789
Fizazi, K., Scher, H. I., Molina, A., Logothetis, C. J., Chi, K. N., Jones, R. J., Staffurth, J. N., North, S., Vogelzang, N. J., Saad, F., et al. (2012) · The Lancet Oncology · doi:10.1016/s1470-2045(12)70379-0 · Cited by 1,384
Veldscholte, J., Ris-Stalpers, C., Kuiper, G. G. J. M., Jenster, G., Berrevoets, C., Claassen, E., van Rooij, H. C. J., Trapman, J., Brinkmann, A. O., & Mulder, E. (1990) · Biochemical and Biophysical Research Communications · doi:10.1016/s0006-291x(05)80067-1 · Cited by 950 · cited 1×
“LNCaP cells express a mutated AR (T877A) [32], while VCaP cells express the wild type AR.”
BackgroundAttard, G., Reid, A. H. M., A'Hern, R., Parker, C., Oommen, N. B., Folkerd, E., Messiou, C., Molife, L. R., Maier, G., Thompson, E., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.20.0642 · Cited by 605
Holzbeierlein, J., Lal, P., LaTulippe, E., Smith, A., Satagopan, J., Zhang, L., Ryan, C., Smith, S., Scher, H., Scardino, P., et al. (2004) · The American Journal of Pathology · doi:10.1016/s0002-9440(10)63112-4 · Cited by 577 · cited 1×
“The AR and AR-regulated genes are expressed in most clinical cases of CRPC demonstrating that the AR axis is reactivated and drives tumour growth [4,5].”
BackgroundStandardization of real-time PCR gene expression data from independent biological replicates
Willems, E., Leyns, L., & Vandesompele, J. (2008) · Analytical Biochemistry · doi:10.1016/j.ab.2008.04.036 · Cited by 490 · cited 1×
“Data from individual experiments was all normalized using log transformation and mean-centering prior to analysis [49].”
MethodInternational epidemiology of prostate cancer: Geographical distribution and secular trends
Baade, P. D., Youlden, D. R., & Krnjacki, L. J. (2009) · Molecular Nutrition & Food Research · doi:10.1002/mnfr.200700511 · Cited by 444 · cited 1×
“Prostate cancer (PCa) is the second most common cancer among men worldwide [1] with androgen deprivation therapy (ADT) being the first line treatment for advanced PCa since androgen signalling is essential for normal and malignant growth of prostate tissue.”
BackgroundCai, C., Chen, S., Ng, P., Bubley, G. J., Nelson, P. S., Mostaghel, E. A., Marck, B., Matsumoto, A. M., Simon, N. I., Wang, H., et al. (2011) · Cancer Research · doi:10.1158/0008-5472.can-11-0532 · Cited by 433 · cited 1×
“A twentyfour hour time point was chosen as significant upregulation of KLK3 and TMPRSS2 has previously been demonstrated at this time point in both LNCaP and VCaP cells [33,34].”
BackgroundDihydrotestosterone synthesis bypasses testosterone to drive castration-resistant prostate cancer
Chang, K.-H., Li, R., Papari-Zareei, M., Watumull, L., Zhao, Y. D., Auchus, R. J., & Sharifi, N. (2011) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1107898108 · Cited by 346
The human androgen receptor: Domain structure, genomic organization and regulation of expression
Brinkmann, A. O., Faber, P. W., van Rooij, H. C. J., Kuiper, G. G. J. M., Ris, C., Klaassen, P., van der Korput, J. A. G. M., Voorhorst, M. M., van Laar, J. H., Mulder, E., et al. (1989) · Journal of Steroid Biochemistry · doi:10.1016/0022-4731(89)90098-8 · Cited by 339 · cited 1×
“2 [22] and the plasmid expressing the human androgen receptor, pSVARo [23] were obtained from Prof.”
MethodVCaP, a cell-based model system of human prostate cancer.
Korenchuk, S., Lehr, J. E., McLean, L. L., Lee, Y.-G., Whitney, S. C., Vessella, R. L., Lin, D. L., & Pienta, K. J. (2001) · PubMed · Cited by 323
Partners in crime: deregulation of AR activity and androgen synthesis in prostate cancer
Knudsen, K. E., & Penning, T. M. (2010) · Trends in Endocrinology & Metabolism · doi:10.1016/j.tem.2010.01.002 · Cited by 293 · cited 1×
“Mechanisms proposed to be responsible for the continued AR activation include up-regulation of AR expression and/or gain-of-function mutations of the AR[6].”
BackgroundConversion of abiraterone to D4A drives anti-tumour activity in prostate cancer
Li, Z., Bishop, A. C., Alyamani, M., Garcia, J. A., Dreicer, R., Bunch, D., Liu, J., Upadhyay, S. K., Auchus, R. J., & Sharifi, N. (2015) · Nature · doi:10.1038/nature14406 · Cited by 256 · cited 1×
“A twentyfour hour time point was chosen as significant upregulation of KLK3 and TMPRSS2 has previously been demonstrated at this time point in both LNCaP and VCaP cells [33,34].”
BackgroundTMPRSS2 : ERG Fusion Identifies a Subgroup of Prostate Cancers with a Favorable Prognosis
Saramäki, O. R., Harjula, A. E., Martikainen, P. M., Vessella, R. L., Tammela, T. L. J., & Visakorpi, T. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-2051 · Cited by 243
Steroid Hormone Receptors in Prostate Cancer: A Hard Habit to Break?
Attard, G., Cooper, C. S., & de Bono, J. S. (2009) · Cancer Cell · doi:10.1016/j.ccr.2009.11.006 · Cited by 242
Inactivation of androgens by UDP-glucuronosyltransferase enzymes in humans
Bélanger, A., Pelletier, G., Labrie, F., Barbier, O., & Chouinard, S. (2003) · Trends in Endocrinology & Metabolism · doi:10.1016/j.tem.2003.10.005 · Cited by 235
Turcu, A. F., Nanba, A. T., Chomic, R., Upadhyay, S. K., Giordano, T. J., Shields, J. J., Merke, D. P., Rainey, W. E., & Auchus, R. J. (2016) · European Journal of Endocrinology · doi:10.1530/eje-15-1181 · Cited by 231
Rege, J., Nakamura, Y., Satoh, F., Morimoto, R., Kennedy, M. R., Layman, L. C., Honma, S., Sasano, H., & Rainey, W. E. (2013) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2012-2912 · Cited by 227 · cited 1×
“11OHA4 is one of the most abundant C19 steroid produced by the human adrenal, both before and after adrenocorticotrophic hormone (ACTH) treatment [17].”
BackgroundMechanisms mediating androgen receptor reactivation after castration
Yuan, X., & Balk, S. P. (2009) · Urologic Oncology: Seminars and Original Investigations · doi:10.1016/j.urolonc.2008.03.021 · Cited by 204 · cited 1×
“The AR and AR-regulated genes are expressed in most clinical cases of CRPC demonstrating that the AR axis is reactivated and drives tumour growth [4,5].”
BackgroundA simple method to measure cell viability in proliferation and cytotoxicity assays
Borra, R. C., Lotufo, M. A., Gagioti, S. M., Barros, F. D. M., & Andrade, P. M. (2009) · Brazilian Oral Research · doi:10.1590/s1806-83242009000300006 · Cited by 200 · cited 1×
“Cell growth was subsequently assessed using a resazurin assay [30,31].”
MethodStorbeck, K.-H., Bloem, L. M., Africander, D., Schloms, L., Swart, P., & Swart, A. C. (2013) · Molecular and Cellular Endocrinology · doi:10.1016/j.mce.2013.07.006 · Cited by 198 · cited 2×
“We showed that at the concentration of 1 nM, 11KT and 11KDHT have androgenic properties comparable to T and DHT, respectively [21].”
BackgroundSelf-citationSwillens, S. (1995) · Molecular Pharmacology · doi:10.1016/s0026-895x(25)08761-9 · Cited by 187 · cited 2×
“Using the dissociation constant (Kd) for Mib reported in Africander et al. [24], the Ki values for DHT, 11KDHT, T and 11KT were determined from heterologous displacement curves using the equation by Swillens [25] which takes ligand depletion into account.”
MethodAndrogen biosynthetic pathways in the human prostate
Luu-The, V., Bélanger, A., & Labrie, F. (2008) · Best Practice & Research Clinical Endocrinology & Metabolism · doi:10.1016/j.beem.2008.01.008 · Cited by 169
Ross, R. W., Xie, W., Regan, M. M., Pomerantz, M., Nakabayashi, M., Daskivich, T. J., Sartor, O., Taplin, M., Kantoff, P. W., & Oh, W. K. (2008) · Cancer · doi:10.1002/cncr.23304 · Cited by 139
Swart, A. C., Schloms, L., Storbeck, K.-H., Bloem, L. M., Toit, T. D., Quanson, J. L., Rainey, W. E., & Swart, P. (2013) · The Journal of Steroid Biochemistry and Molecular Biology · doi:10.1016/j.jsbmb.2013.04.010 · Cited by 125 · cited 1×
“In addition to DHEA and A4, the human adrenal gland produces substantial amounts of the inactive C19 steroid 11β-hydroxyandrostenedione (11OHA4) [16–18] via the cytochrome P450 11β-hydroxylase (CYP11B1) catalysed hydroxylation of A4 [19,20].”
BackgroundSelf-citationSteroid biosynthesis and prostate cancer
Sharifi, N., & Auchus, R. J. (2012) · Steroids · doi:10.1016/j.steroids.2012.03.015 · Cited by 116
Schauwaers, K., De Gendt, K., Saunders, P. T. K., Atanassova, N., Haelens, A., Callewaert, L., Moehren, U., Swinnen, J. V., Verhoeven, G., Verrijdt, G., et al. (2007) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0610814104 · Cited by 115 · cited 1×
“2 [22] and the plasmid expressing the human androgen receptor, pSVARo [23] were obtained from Prof.”
MethodSchloms, L., Storbeck, K., Swart, P., Gelderblom, W. C. A., & Swart, A. C. (2011) · The Journal of Steroid Biochemistry and Molecular Biology · doi:10.1016/j.jsbmb.2011.11.003 · Cited by 102 · cited 1×
“In addition to DHEA and A4, the human adrenal gland produces substantial amounts of the inactive C19 steroid 11β-hydroxyandrostenedione (11OHA4) [16–18] via the cytochrome P450 11β-hydroxylase (CYP11B1) catalysed hydroxylation of A4 [19,20].”
BackgroundSelf-citationYazawa, T., Uesaka, M., Inaoka, Y., Mizutani, T., Sekiguchi, T., Kajitani, T., Kitano, T., Umezawa, A., & Miyamoto, K. (2008) · Endocrinology · doi:10.1210/en.2007-1015 · Cited by 95
de Launoit, Y., Veilleux, R., Dufour, M., Simard, J., & Labrie, F. (1991) · PubMed · Cited by 90
Androgen metabolism in prostate cancer: from molecular mechanisms to clinical consequences
Chang, K.-H., Ercole, C. E., & Sharifi, N. (2014) · British Journal of Cancer · doi:10.1038/bjc.2014.268 · Cited by 85
Androgen receptor mediates the expression of UDP‐glucuronosyltransferase 2 B15 and B17 genes
Bao, B., Chuang, B., Wang, Q., Sartor, O., Balk, S. P., Brown, M., Kantoff, P. W., & Lee, G. M. (2008) · The Prostate · doi:10.1002/pros.20749 · Cited by 79
Bohrer, L. R., Chen, D., Hallstrom, T. C., & Huang, H. (2010) · Endocrinology · doi:10.1210/en.2010-0436 · Cited by 76 · cited 12×
“Interestingly, differences between T and 11KT induced expression were statistically significant for KLK3 (10 nM treatment) and FKBP5 (1 and 10 nM treatments), and approached significance for TMPRSS2 (p = 0.052, 1 nM treatment; p = 0.053, 10 nM treatment). doi:10.1371/journal.pone.0159867.g003 PLOS ONE | DOI:10.1371/jo…”
InfluentialVellaichamy, A., Sreekumar, A., Strahler, J. R., Rajendiran, T., Yu, J., Varambally, S., Li, Y., Omenn, G. S., Chinnaiyan, A. M., & Nesvizhskii, A. I. (2009) · PLoS ONE · doi:10.1371/journal.pone.0007075 · Cited by 71
Swart, A. C., & Storbeck, K.-H. (2015) · Molecular and Cellular Endocrinology · doi:10.1016/j.mce.2014.12.009 · Cited by 68
Self-citationAndrogen-Responsive Gene Database: Integrated Knowledge on Androgen-Responsive Genes
Jiang, M., Ma, Y., Chen, C., Fu, X., Yang, S., Li, X., Yu, G., Mao, Y., Xie, Y., & Li, Y. (2009) · Molecular Endocrinology · doi:10.1210/me.2009-0103 · Cited by 68
Africander, D., Toit, R. L.-D., Verhoog, N. J. D., Noeth, D. J., & Hapgood, J. P. (2011) · Contraception · doi:10.1016/j.contraception.2011.06.006 · Cited by 67 · cited 1×
“Cells were lysed and analysed as previously described [26], with the exception that the protein concentration in the lysate was determined by the Pierce BCA method (Pierce Chemical).”
MethodSelf-citationResazurin Metabolism Assay Is a New Sensitive Alternative Test in Isolated Pig Cornea
Perrot, S., Dutertre-Catella, H., Martin, C., Rat, P., & Warnet, J.-M. (2003) · Toxicological Sciences · doi:10.1093/toxsci/kfg014 · Cited by 64 · cited 1×
“Cell growth was subsequently assessed using a resazurin assay [30,31].”
MethodAfricander, D., Storbeck, K., & Hapgood, J. P. (2014) · The Journal of Steroid Biochemistry and Molecular Biology · doi:10.1016/j.jsbmb.2014.05.007 · Cited by 63 · cited 1×
“[24], the Ki values for DHT, 11KDHT, T and 11KT were determined from heterologous displacement curves using the equation by Swillens [25] which takes ligand depletion into account.”
MethodSelf-citation11β-Hydroxyandrostenedione Returns to the Steroid Arena: Biosynthesis, Metabolism and Function
Bloem, L., Storbeck, K.-H., Schloms, L., & Swart, A. (2013) · Molecules · doi:10.3390/molecules181113228 · Cited by 60
Self-citationModulation of Androgen Receptor Signaling in Hormonal Therapy-Resistant Prostate Cancer Cell Lines
Marques, R. B., Dits, N. F. J., Erkens‐Schulze, S., van IJcken, W. F. J., van Weerden, W. M., & Jenster, G. W. (2011) · PLoS ONE · doi:10.1371/journal.pone.0023144 · Cited by 56
The 5α-androstanedione pathway to dihydrotestosterone in castration-resistant prostate cancer
Sharifi, N. (2012) · Journal of Investigative Medicine · doi:10.2310/jim.0b013e31823874a4 · Cited by 52
Regulation of Human UGT2B15 and UGT2B17 by miR-376c in Prostate Cancer Cell Lines
Wijayakumara, D., Hu, D. G., Meech, R., McKinnon, R. A., & Mackenzie, P. I. (2015) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.115.226118 · Cited by 51
Expert Opinion on Optimal Testosterone Control in Prostate Cancer
Zlotta, A., & Debruyne, F. M. J. (2005) · European Urology Supplements · doi:10.1016/j.eursup.2005.08.005 · Cited by 48
Kumagai, J., Hofland, J., Erkens-Schulze, S., Dits, N. F. J., Steenbergen, J., Jenster, G., Homma, Y., de Jong, F. H., & van Weerden, W. M. (2013) · The Prostate · doi:10.1002/pros.22655 · Cited by 46
Pinthus (2010) · International Journal of Oncology · doi:10.3892/ijo_00000725 · Cited by 37
Rowland, J. G., Robson, J. L., Simon, W. J., Leung, H. Y., & Slabas, A. R. (2006) · PROTEOMICS · doi:10.1002/pmic.200600697 · Cited by 32
Shao, C., Wang, Y., Yue, H., Zhang, Y., Shi, C., Liu, F., Ting-yi, B., Yang, Z., Yuan, J., & Shao, G.-X. (2007) · Journal of Andrology · doi:10.2164/jandrol.106.002154 · Cited by 25
Williamson, S. C., Mitter, R., Hepburn, A. C., Wilson, L., Mantilla, A., Leung, H. Y., Robson, C. N., & Heer, R. (2013) · British Journal of Cancer · doi:10.1038/bjc.2013.399 · Cited by 14
Androstenedione Is the Preferred Androgen Source in Hormone Refractory Prostate Cancer—Letter
Sharifi, N., & Auchus, R. J. (2014) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-14-1123 · Cited by 11
Schloms, L., Storbeck, K., Swart, P., Gelderblom, W. C. A., & Swart, A. C. (2012) · The Journal of Steroid Biochemistry and Molecular Biology · doi:10.1016/j.jsbmb.2012.08.013 · Cited by 2
Self-citation
Cited by
Congenital adrenal hyperplasia
El-Maouche, D., Arlt, W., & Merke, D. P. (2017) · The Lancet · doi:10.1016/s0140-6736(17)31431-9 · Cited by 669
Witchel, S. F., Oberfield, S. E., & Peña, A. S. (2019) · Journal of the Endocrine Society · doi:10.1210/js.2019-00078 · Cited by 653
“Testosterone, DHT, 11-ketotestosterone, and 11-ketodihydrotestosterone bind to the human ARand promote AR-regulated gene expression [33].”
BackgroundSchiffer, L., Barnard, L., Baranowski, E. S., Gilligan, L. C., Taylor, A. E., Arlt, W., Shackleton, C. H. L., & Storbeck, K.-H. (2019) · The Journal of Steroid Biochemistry and Molecular Biology · doi:10.1016/j.jsbmb.2019.105439 · Cited by 450
Self-citation11-Oxygenated C19 steroids are the predominant androgens in polycystic ovary syndrome
O’Reilly, M. W., Kempegowda, P., Jenkinson, C., Taylor, A. E., Quanson, J. L., Storbeck, K.-H., & Arlt, W. (2017) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2016-3285 · Cited by 267
Self-citationSteroidogenesis: Unanswered Questions
Miller, W. L. (2017) · Trends in Endocrinology & Metabolism · doi:10.1016/j.tem.2017.09.002 · Cited by 226
Metadata
- Authors
- Pretorius, E., Africander, D. J., Vlok, M., Perkins, M. S., Quanson, J., & Storbeck, K.-H.
- Affiliations
- Stellenbosch University (ZA)
- Corresponding author
- Pretorius, Elzette
- Africander, Donita J.
- Vlok, Maré
- Perkins, Meghan S.
- Quanson, Jonathan
- Storbeck, Karl-Heinz
- ORCID
- Venue
- PLOS ONE
- Publisher
- Public Library of Science (PLoS)
- Published
- 2016-07-21
- Volume
- 11
- Issue
- 7
- Pages
- e0159867
- ISSN
- 1932-6203 (ISSN-L)
- PMC
- PMC4956299
- OpenAlex
- W2501835417
- Cited by
- 148
- References
- 55
- Citations by year
- 2026: 14 · 2025: 10 · 2024: 11 · 2023: 13 · 2022: 18 · 2021: 20 · 2020: 20 · 2019: 15 · 2018: 12 · 2017: 11 · 2016: 4
- FWCI
- 12.52
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- PLoS ONE (publishedVersion, cc-by)
- Europe PMC (PubMed Central) (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- SUNScholar (Stellenbosch University) (submittedVersion)
- Funders
- National Research Foundation of South Africa (TTK1206061092)
- Cancer Association of South Africa
- Universiteit Stellenbosch
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Prostate Cancer Treatment and Research
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Hormonal and reproductive studies
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Endocrinology › Estrogen and related hormone effects
- Keywords
- 11-ketotestosterone, castration-resistant prostate cancer, androgen receptor, 11β-hydroxyandrostenedione, androgen metabolism, androgen-dependent gene expression, prostate cancer cell proliferation, LNCaP cells, VCaP cells
- MeSH terms
- Androgens, Animals, Humans, Male, Protein Binding, Receptors, Androgen, Testosterone, Response Elements, Cell Line, Tumor, Cell Proliferation, Biosynthetic Pathways, Prostatic Neoplasms, Castration-Resistant
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.